

REMARKS

Review and reconsideration on the merits are requested.

Applicants elect the claim of Group III, claim 11, drawn to a method of prevention or treatment. Election is with traverse for the reasons later presented.

Applicants further elect “ethyl(-)-2-[4-[2-[[$(1S,2R)$]-2-hydroxy-2-(4-hydroxyphenyl)-1-ethylethyl]amino]ethyl]-2,5-dimethylphenoxy]acetate” from the phenoxyacetic acid derivative represented by the general formula (I), and “silodosin” from the $\alpha 1$ adrenoceptor blocker.

Claims 11-14 and 17 include the elected species.

As the Examiner will see, new claims 12-18 largely parallel those claims set forth as claims 2-9 except for being in method form.

Applicants traverse on the rather straight forward basis that the “special technical feature” of each Group is the phenoxyacetic acid derivative of general formula (I) and an alpha one-adrenoceptor blocker.

Applicants further traverse on the ground that the Examiner has quite clearly misunderstood the special technical features of the various Groups as set forth at page 3 of the present Action. The special technical feature is as set forth above regarding Applicant's traversal.

Withdrawal of the Restriction Requirement is requested.


AMENDMENT/RESPONSE TO ELECTION/RESTRICTIONS

Application No.: 10/599,203

Attorney Docket No.: Q96974

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 16, 2008